微小RNA在胰腺癌诊断与治疗中价值的研究进展

Role of microR NAs in diagnosis and treatment of pancreatic cancer

胰腺癌是消化系常见的恶性肿瘤之一,由于胰腺癌早期易侵袭转移的特性,确诊时超过80%已属晚期,仅有约10%-20%患者能进行根治性手术,对那些临床上有机会进行了根治性手术切除的胰腺癌患者,术后也绝大多数因复发、远处转移和化疗耐药,5年生存率仍不超过6%.胰腺癌已成为严重威胁人类健康的疾病之一.因此,目前迫切需要探寻新的、可靠的肿瘤标志物和分子治疗靶点.微小RNA(micro RNA,mi RNA)与肿瘤的关系成为近年来肿瘤学研究的热点,大量研究表明很多mi RNAs的表达水平与胰腺癌的发生与发展、诊断与治疗、预后等都有着密切关系,被认为是一组新的癌基因或抑癌基因,这给胰腺癌的诊断与治疗带来了新的希望.

Pancreatic cancer is a malignant tumor of the digestive system. Due to its early metastatic nature, more than 80% of pancreatic cancer patients have invasive disease at the time of diagnosis, and only about 10%-20% of patients are suitable for radical surgery. For patients who have the opportunity to undergo radical resection of pancreatic cancer, most will develop postoperative recurrence, distant metastasis and resistance to chemotherapy. As a result, the 5-year survival rate is still less than 6%. Therefore, pancreatic cancer has become a serious threat to human health. Therefore, there is an urgent need to find new reliable tumor markers and molecular therapeutic targets. In recent years, micro RNAs（miRNAs） have gradually become a hotspot in the research of tumors. Increasing data indicate that miR NAs are involved in tumor development and progression, diagnosis, treatment and so on. mi RNAs are considered to be a new set of oncogenes or tumor suppressor genes, and they brought new hope to the diagnosis and treatment of pancreatic cancer.